These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 6849295

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.
    Des Prez RM, Bryan CS, Hawiger J, Colley DG.
    Infect Immun; 1975 Jun; 11(6):1235-43. PubMed ID: 806523
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD, Fearon DT, Silbert JE, Austen KF.
    J Exp Med; 1979 Nov 01; 150(5):1202-15. PubMed ID: 501288
    [Abstract] [Full Text] [Related]

  • 7. Equine alternative pathway activation by unsensitized rabbit red blood cells.
    Leid RW, Coley SC, Blanchard DP, Perryman LE.
    Vet Immunol Immunopathol; 1985 May 01; 9(1):71-85. PubMed ID: 4024451
    [Abstract] [Full Text] [Related]

  • 8. Feline (cat) hemolytic complement optimal testing conditions.
    Barta O, Oyekan PP.
    Am J Vet Res; 1981 Mar 01; 42(3):378-81. PubMed ID: 6791533
    [Abstract] [Full Text] [Related]

  • 9. Determination of optimal in vitro conditions for caprine alternative complement pathway assay.
    Venugopal G, Ram GC, Bansal MP.
    Vet Immunol Immunopathol; 1992 May 01; 32(3-4):359-64. PubMed ID: 1632071
    [Abstract] [Full Text] [Related]

  • 10. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway.
    Boackle RJ, Caughman GB, Vesely J, Medgyesi G, Fudenberg HH.
    Mol Immunol; 1983 Nov 01; 20(11):1157-64. PubMed ID: 6228720
    [Abstract] [Full Text] [Related]

  • 11. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces.
    Kirschfink M, Kovacs B, Mottaghy K.
    Circ Shock; 1993 Jul 01; 40(3):221-6. PubMed ID: 8348684
    [Abstract] [Full Text] [Related]

  • 12. The classical and alternate pathways of complement in oral contraceptive users.
    Delâge JM, Lehner-Netsch G, Brisson J.
    Contraception; 1987 Dec 01; 36(6):627-32. PubMed ID: 3446439
    [Abstract] [Full Text] [Related]

  • 13. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor.
    Czop JK, Austen KF.
    J Immunol; 1985 Nov 01; 135(5):3388-93. PubMed ID: 4045195
    [Abstract] [Full Text] [Related]

  • 14. Hemolytic assay for goat (caprine) and swine (porcine) complement.
    Oyekan PP, Barta O.
    Vet Immunol Immunopathol; 1980 Dec 01; 1(4):317-28. PubMed ID: 15615050
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
    Schenkein HA, Ruddy S.
    J Immunol; 1981 Jan 01; 126(1):7-10. PubMed ID: 6778918
    [Abstract] [Full Text] [Related]

  • 18. Studies on activation and levels of haemolytic complement of buffalo (Bubalus bubalis). II. Alternate complement pathway activity in serum.
    Arya A, Goel MC.
    Vet Immunol Immunopathol; 1992 Jan 31; 30(4):411-8. PubMed ID: 1546445
    [Abstract] [Full Text] [Related]

  • 19. Natural hemolytic and bactericidal activities of sea bream Sparus aurata serum are effected by the alternative complement pathway.
    Sunyer JO, Tort L.
    Vet Immunol Immunopathol; 1995 Apr 31; 45(3-4):333-45. PubMed ID: 7676614
    [Abstract] [Full Text] [Related]

  • 20. [Modification of proteolytic complement cascade after treatment with exogenous heparin].
    Galebskaia LV, Solovtsova IL, Riumina EV.
    Vopr Med Khim; 2001 Apr 31; 47(1):91-7. PubMed ID: 11386002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.